Avidity Biosciences, Inc.
RNA
$26.57
-$1.53-5.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.57% | -17.10% | -11.70% | 58.67% | -20.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.57% | -17.10% | -11.70% | 58.67% | -20.80% |
| Cost of Revenue | 81.05% | 61.79% | 49.84% | 39.92% | 15.80% |
| Gross Profit | -83.02% | -66.74% | -53.37% | -39.00% | -18.17% |
| SG&A Expenses | 75.80% | 69.52% | 68.85% | 15.20% | 55.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.82% | 63.52% | 54.09% | 34.93% | 23.11% |
| Operating Income | -81.28% | -67.39% | -56.98% | -34.01% | -25.40% |
| Income Before Tax | -69.18% | -53.55% | -50.54% | -31.42% | -19.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.18% | -53.55% | -50.54% | -31.42% | -19.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.18% | -53.55% | -50.54% | -31.42% | -19.76% |
| EBIT | -81.28% | -67.39% | -56.98% | -34.01% | -25.40% |
| EBITDA | -81.85% | -67.80% | -57.26% | -33.81% | -25.14% |
| EPS Basic | -0.13% | 7.77% | -0.52% | -6.13% | 9.77% |
| Normalized Basic EPS | -0.14% | 7.77% | -0.51% | -6.13% | 9.79% |
| EPS Diluted | -0.13% | 7.77% | -0.52% | -6.13% | 9.77% |
| Normalized Diluted EPS | -0.14% | 7.77% | -0.51% | -6.13% | 9.79% |
| Average Basic Shares Outstanding | 68.96% | 66.50% | 49.78% | 23.82% | 32.74% |
| Average Diluted Shares Outstanding | 68.96% | 66.50% | 49.78% | 23.82% | 32.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
